keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy bladder cancer

keyword
https://www.readbyqxmd.com/read/28720358/prognostic-significance-of-neutrophilic-infiltration-in-benign-lymph-nodes-in-patients-with-muscle-invasive-bladder-cancer
#1
Sumanta K Pal, Anh Pham, Winston Vuong, Xueli Liu, Yulan Lin, Nora Ruel, Bertram E Yuh, Kevin Chan, Timothy Wilson, Seth P Lerner, David McConkey, Richard Jove, Wei Liang
BACKGROUND: Preclinical studies suggest that signal transducer and activator of transcription 3 (STAT3)-mediated recruitment of neutrophils to premetastatic tissue occurs prior to metastatic progression. OBJECTIVE: We sought to determine if neutrophilic infiltration in benign nodal tissue is associated with poor clinical outcome in patients with muscle-invasive bladder cancer. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded tissue was secured from 55 patients with muscle-invasive bladder cancer who had undergone cystectomy at our institution...
February 2017: European Urology Focus
https://www.readbyqxmd.com/read/28675174/landmarks-in-the-treatment-of-muscle-invasive-bladder-cancer
#2
REVIEW
Niyati Lobo, Chloe Mount, Kawa Omar, Rajesh Nair, Ramesh Thurairaja, Muhammad Shamim Khan
Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity and mortality. Radical cystectomy is the mainstay of treatment and has evolved since the first reported cystectomy in 1887 to include pelvic lymph node dissection and the creation of increasingly sophisticated urinary diversions, such as neobladders and pouches, which enable patients to maintain continence. Pioneering work in the 1970s established the therapeutic activity of cisplatin in patients with bladder cancer and resulted in the introduction of cisplatin-based neoadjuvant chemotherapy, which led to the first improvement in survival outcomes in decades...
July 4, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28674853/fdg-pet-ct-for-response-evaluation-of-invasive-bladder-cancer-following-neoadjuvant-chemotherapy
#3
E E Fransen van de Putte, E Vegt, L S Mertens, A Bruining, K Hendricksen, M S van der Heijden, S Horenblas, B W G van Rhijn
PURPOSE: We investigated the accuracy of FDG-PET/CT response identification following neoadjuvant or induction chemotherapy (NAIC) for invasive bladder cancer (BC) as to better select patients for radical cystectomy (RC). METHODS: Between 2010 and 2014, 37 cT1-4N1-3 BC patients received a FDG-PET/CT before and after NAIC followed by RC. Metabolic lymph node (LN) response was evaluated according to EORTC recommendations. Additionally, primary tumor response was evaluated for 23 patients by means of delayed pelvic imaging after forced diuresis...
July 3, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28650267/robotic-assisted-radical-cystectomy-versus-open-radical-cystectomy-for-management-of-bladder-cancer-review-of-literature-and-randomized-trials
#4
Kyrollis Attalla, Marissa Kent, Nikhil Waingankar, Reza Mehrazin
Among the many milestones in the last several decades in the management of muscle-invasive bladder cancer and high-risk nonmuscle-invasive bladder cancer including the extension of the standard lymph node dissection and the use of neoadjuvant chemotherapy, minimally invasive techniques have gained traction as an attractive option for radical cystectomy. Open radical cystectomy is plagued with high rates of perioperative and postoperative morbidity and mortality, and as robotic assistance has demonstrated benefits in other arenas of surgery and urology, the evolution of the approach to radical cystectomy has likewise incorporated robotic assistance...
June 2017: Future Oncology
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#5
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
June 20, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28625029/-a-case-of-squamous-cell-carcinoma-in-bladder-diverticulum-producing-granulocyte-colony-stimulating-factor
#6
Koichi Uemura, Kazuhiro Namura, Susumu Umemoto, Osamu Matsubara, Koichi Udagawa
We report a rare case of squamous cell carcinoma (SCC) in bladder diverticulum producing granulocyte colony stimulating factor (G-CSF). A 59-year-old man complaining of hematuria and right hip pain was admitted with a large cancer in the bladder diverticulum. His laboratory data showed leukocytosis of 20,100/ μ l (neutrophils : 92%) with an elevated G-CSF of 76. 6 pg/ml in the peripheral blood. After neoadjuvant chemotherapy (gemcitabine and cisplatin), radical cystectomy was performed to normalize serum leukocytosis and G-CSF...
May 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28625005/dose-dense-mvac-prior-to-radical-cystectomy-a-real-world-experience
#7
Homayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, Kylea R Potvin, Kamran Zargar-Shoshtari, Bas W van Rhijn, Siamak Daneshmand, Jeff M Holzbeierlein, Philippe E Spiess, Eric Winquist, Simon Horenblas, Colin Dinney, Peter C Black, Wassim Kassouf
PURPOSE: Our primary endpoint was to assess pathological response rate (pT0N0 and ≤pT1N0) for patients with BCa treated with the accelerated or dose dense MVAC (ddMVAC) chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort. MATERIALS AND METHODS: We retrospectively reviewed records of patients with urothelial cancer who underwent ddMVAC and RC at seven contributing institutions from 2000 to 2015. Patients with cT2-4a, M0 BCa were included...
June 17, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28558988/association-of-distance-to-treatment-facility-with-survival-and-quality-outcomes-after-radical-cystectomy-a-multi-institutional-study
#8
Ahmed Q Haddad, Ryan Hutchinson, Erika L Wood, Gus Miranda, Boris Gershman, Jamie Messer, Robert Svatek, Peter C Black, Stephen A Boorjian, Jay Shah, Siamak Daneshmand, Yair Lotan
BACKGROUND: We sought to determine the effect of the travel distance on mortality and quality outcomes after radical cystectomy in a large multi-institutional cohort. PATIENTS AND METHODS: A total of 3957 patients who had undergone radical cystectomy for urothelial carcinoma at 6 North American tertiary care institutions were included. The association of travel distance with quality-of-care endpoints, 90-day mortality, and long-term survival were evaluated. RESULTS: The median patient age was 69 years (interquartile range, 61-76 years), and most patients were men (80%)...
May 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28545841/oncologic-outcomes-for-patients-with-residual-cancer-at-cystectomy-following-neoadjuvant-chemotherapy-a-pathologic-stage-matched-analysis
#9
Bimal Bhindi, Igor Frank, Ross J Mason, Robert F Tarrell, Prabin Thapa, John C Cheville, Brian A Costello, Lance C Pagliaro, R Jeffrey Karnes, R Houston Thompson, Matthew K Tollefson, Stephen A Boorjian
While it has been demonstrated that receipt of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) improves survival compared to RC alone, the driving factor for this benefit may be from patients with ypT0 status at surgery. Meanwhile, the implications of having residual urothelial carcinoma of the bladder (rUCB) at RC after NAC are less clear. We therefore evaluated whether survival differed between patients with rUCB at RC after NAC and stage-matched controls who underwent RC alone. Patients who underwent NAC + RC (n = 180) were matched to controls who underwent RC alone (n=324) on the basis of pT and pN stage, margin status, and year of RC...
May 22, 2017: European Urology
https://www.readbyqxmd.com/read/28500617/post-chemotherapy-pd-l1-expression-correlates-with-clinical-outcomes-in-japanese-bladder-cancer-patients-treated-with-total-cystectomy
#10
Daisuke Noro, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Toshiaki Kawaguchi, Chikara Ohyama
Programmed cell death ligand-1 (PD-L1) is a key target molecule of immunotherapy that is frequently overexpressed in bladder cancer. In the present study, we examined whether PD-L1 expression is associated with clinical outcomes in bladder cancer patients. We enrolled 102 bladder cancer patients treated with cystectomy at the Aomori Prefectural Hospital between April 2004 and May 2014. We conducted an immunohistochemical examination of PD-L1 expression using the SP142 assay. PD-L1 expression was scored at three diagnostic levels (0/1/2)...
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28481707/immune-checkpoint-blockade-in-metastatic-urothelial-cancer
#11
Arjun Vasant Balar
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
July 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28469299/systemic-therapy-in-bladder-cancer
#12
REVIEW
Ian G Pinto
Systemic chemotherapy is essential for the management of muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer (BCa). Neoadjuvant chemotherapy is key to the management of MIBC with many cisplatin-based regimens. Adjuvant chemotherapy may be considered for selected patients who did not receive neoadjuvant therapy. Systemic chemotherapy with radiotherapy is a critical component of a trimodal bladder-preserving approach and is superior to radiotherapy alone. Cisplatin-based chemotherapy has been the mainstay for metastatic BCa...
April 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28469298/where-are-we-with-bladder-preservation-for-muscle-invasive-bladder-cancer-in-2017
#13
REVIEW
Woodson Wade Smelser, Marcus A Austenfeld, Jeffrey Maxwell Holzbeierlein, Eugene Kang Lee
INTRODUCTION: In 2017, neoadjuvant, cisplatin-based chemotherapy followed by radical cystectomy (RC) is considered the gold standard therapy for muscle-invasive bladder based on randomized controlled trials. Across all tumor stages, this approach has been associated with the highest rates of disease-specific survival. However, RC is one of the most challenging procedures performed by urologic surgeons and carries with it significant risks of complications, hospital readmission, and even a small risk of mortality, in addition to lifestyle changes that can have long-term effects on well-being...
April 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28460994/erectile-dysfunction-treatment-following-radical-cystoprostatectomy-analysis-of-a-nationwide-insurance-claims-database
#14
Meera R Chappidi, Max Kates, Nikolai A Sopko, Gregory A Joice, Jeffrey J Tosoian, Phillip M Pierorazio, Trinity J Bivalacqua
INTRODUCTION: To improve care for patients after radical cystoprostatectomy (RCP), focus on survivorship issues such as sexual function needs to increase. Previous studies have demonstrated the burden of erectile dysfunction (ED) after RCP to be as high as 89%. AIM: To determine the rates of ED treatment use (phosphodiesterase type 5 inhibitors, injectable therapies, urethral suppositories, vacuum erection devices, and penile prosthetics) in patients with bladder cancer before and after RCP to better understand current patterns of care...
June 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28453896/clinical-and-patient-reported-outcomes-of-spare-a-randomised-feasibility-study-of-selective-bladder-preservation-versus-radical-cystectomy
#15
R A Huddart, A Birtle, L Maynard, M Beresford, J Blazeby, J Donovan, J D Kelly, T Kirkbank, D B McLaren, G Mead, C Moynihan, R Persad, C Scrase, R Lewis, E Hall
OBJECTIVES: To test the feasibility of a randomised trial in muscle invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy or selective bladder preservation, where definitive treatment (cystectomy or radiotherapy) is determined by response to chemotherapy. PATIENTS AND METHODS: SPARE is a multicentre randomised controlled trial comparing radical cystectomy and selective bladder preservation in patients with MIBC staged T2-3 N0 M0, fit for both treatment strategies and receiving three cycles of neoadjuvant chemotherapy...
April 28, 2017: BJU International
https://www.readbyqxmd.com/read/28447581/effect-of-cisplatin-based-neoadjuvant-chemotherapy-on-survival-in-patients-with-bladder-cancer-a-meta-analysis
#16
Gang Li, Hui-Min Niu, Hong-Tao Wu, Bao-Yu Lei, Xiao-Hua Wang, Xiao-Bo Guo, Shu-Lin Feng
PURPOSE: Cisplatin-based neoadjuvant chemotherapy (NAC) has been shown to improve survival in patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy as compared with patients who underwent surgery alone. It has also been suggested as current standard of care in surgically-fit patients with MIBC. This meta-analysis assessed the effect of cisplatin-based NAC on survival in patients with bladder cancer. SOURCE: PubMed, CENTRAL, and Embase were searched until November 22, 2016...
April 26, 2017: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/28433377/neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer-are-things-now-getting-personal
#17
EDITORIAL
Matthew D Galsky, John P Sfakianos, Bart S Ferket
No abstract text is available yet for this article.
April 19, 2017: European Urology
https://www.readbyqxmd.com/read/28410909/neoadjuvant-chemotherapy-in-elderly-patients-with-bladder-cancer-oncologic-outcomes-from-a-single-institution-experience
#18
Andrew R Leone, Kamran Zargar-Shoshtari, Gregory J Diorio, Pranav Sharma, David Boulware, Scott M Gilbert, Julio M Powsang, Jingsong Zhang, Wade J Sexton, Philippe E Spiess, Michael A Poch
INTRODUCTION: We conducted this study to determine if, in appropriately selected elderly patients receiving neoadjuvant chemotherapy (NAC), clinical outcomes including pathologic complete response/downstaging and overall survival were similar to a younger cohort. METHODS: Chart review was performed on patients receiving NAC for urothelial carcinoma of the bladder (UCB) from 2004 to 2013. A total of 116 patients were identified that underwent NAC from 2004 to 2013 for ≥ cT2N0M0 UCB...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28408175/an-oncofetal-glycosaminoglycan-modification-provides-therapeutic-access-to-cisplatin-resistant-bladder-cancer
#19
Roland Seiler, Htoo Zarni Oo, Davide Tortora, Thomas M Clausen, Chris K Wang, Gunjan Kumar, Marina Ayres Pereira, Maj S Ørum-Madsen, Mette Ø Agerbæk, Tobias Gustavsson, Mie A Nordmaj, Jamie R Rich, Nada Lallous, Ladan Fazli, Sherry S Lee, James Douglas, Tilman Todenhöfer, Shaghayegh Esfandnia, Dulguun Battsogt, John S Babcook, Nader Al-Nakouzi, Simon J Crabb, Igor Moskalev, Bernhard Kiss, Elai Davicioni, George N Thalmann, Paul S Rennie, Peter C Black, Ali Salanti, Mads Daugaard
BACKGROUND: Although cisplatin-based neoadjuvant chemotherapy (NAC) improves survival of unselected patients with muscle-invasive bladder cancer (MIBC), only a minority responds to therapy and chemoresistance remains a major challenge in this disease setting. OBJECTIVE: To investigate the clinical significance of oncofetal chondroitin sulfate (ofCS) glycosaminoglycan chains in cisplatin-resistant MIBC and to evaluate these as targets for second-line therapy. DESIGN, SETTING, AND PARTICIPANTS: An ofCS-binding recombinant VAR2CSA protein derived from the malaria parasite Plasmodium falciparum (rVAR2) was used as an in situ, in vitro, and in vivo ofCS-targeting reagent in cisplatin-resistant MIBC...
April 10, 2017: European Urology
https://www.readbyqxmd.com/read/28399521/neoadjuvant-chemotherapy-with-gemcitabine-plus-cisplatin-in-patients-with-locally-advanced-bladder-cancer
#20
Dora Niedersüss-Beke, Thomas Puntus, Thomas Kunit, Birgit Grünberger, Michael Lamche, Wolfgang Loidl, Reinhard Böhm, Nicole Kraischits, Stefan Kudlacek, Paul Schramek, Johannes G Meran
BACKGROUND: Neoadjuvant chemotherapy with methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) is the standard of care for muscle-invasive urothelial bladder cancer. Gemcitabine plus cisplatin (GC) shows similar efficacy with less toxicity in the metastatic setting and has therefore often been used interchangeably with MVAC. We report on the efficacy and safety of neoadjuvant GC in patients with locally advanced urothelial cancer. MATERIALS AND METHODS: We prospectively evaluated 87 patients in 2 centers...
2017: Oncology
keyword
keyword
40909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"